QNCX Stock Analysis: Buy, Sell, or Hold?
QNCX - Quince Therapeutics, Inc. Common Stock
$0.17
-0.10 (-37.06%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 03, 2026
Get Alerted When QNCX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called QNCX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: QNCX is down 94.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: QNCX is down 94.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: QNCX is currently trading at $0.17, which is considered oversold relative to its 30-day fair value range of $2.13 to $3.78.
Technical Outlook: Technically, QNCX is in a uptrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 37.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.67 (+2738.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNCX is in a uptrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 37.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.67 (+2738.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.13 -
$3.78
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
72.1%
Protect Your Profits
Holding QNCX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-37.1%)
- BULLISH: Trading 2738.5% below Wall St target ($7.67)
- WARNING: Recommendation downgraded due to -94.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.13 -
$3.78
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.23
Resistance Level
$3.72
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.38
Wall Street Target
$7.67
(+2738.5%)
Last updated: January 30, 2026 4:09 PM ET
Data refreshes hourly during market hours. Next update: 5:09 PM
Data refreshes hourly during market hours. Next update: 5:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNCX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
Advanced QNCX Option Strategies
Professional options setups generated by AI based on today's QNCX price and gamma walls.
